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ABSTRACT
The Glasgow Outcome Scale (GOS) is the primary endpoint for efficacy analysis of clinical tri-
als in traumatic brain injury (TBI). Accurate and consistent assessment of outcome after TBI
is essential to the evaluation of treatment results, particularly in the context of multicenter stud-
ies and trials. The inconsistent measurement or interobserver variation on GOS outcome, or
for that matter, on any outcome scales, may adversely affect the sensitivity to detect treatment
effects in clinical trial. The objective of this study is to examine effects of nondifferential mis-
classification of the widely used five-category GOS outcome scale and in particular to assess the
impact of this misclassification on detecting a treatment effect and statistical power. We fol-
lowed two approaches. First, outcome differences were analyzed before and after correction for
misclassification using a dataset of 860 patients with severe brain injury randomly sampled from
two TBI trials with known differences in outcome. Second, the effects of misclassification on
outcome distribution and statistical power were analyzed in simulation studies on a hypotheti-
cal 800-patient dataset. Three potential patterns of nondifferential misclassification (random,
upward and downward) on the dichotomous GOS outcome were analyzed, and the power of
finding treatments differences was investigated in detail. All three patterns of misclassification
reduce the power of detecting the true treatment effect and therefore lead to a reduced esti-
mation of the true efficacy. The magnitude of such influence not only depends on the size of the
misclassification, but also on the magnitude of the treatment effect. In conclusion, nondiffer-
ential misclassification directly reduces the power of finding the true treatment effect. An aware-
ness of this procedural error and methods to reduce misclassification should be incorporated
in TBI clinical trials.
Key words: clinical trial; Glasgow Outcome Scale; misclassifications; observer variation; power; trau-
matic brain injury
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INTRODUCTION
ACCURATE AND CONSISTENT ASSESSMENT of outcomeafter traumatic brain injury (TBI) is essential to the
evaluation of treatment results, particularly in the context
of multicenter studies and trials. Various studies have in-
vestigated inter-observer agreement and misclassification
of TBI outcome measures commonly used in TBI stud-
ies, and in general found that interobserver variation or
misclassification on Glasgow Outcome Scale (GOS) out-
come does exist (Anderson et al., 1993; Brooks et al.,
1986; Choi et al., 2002; Maas et al., 1983; Marmarou,
2001; Pettigrew et al., 2003; Scheibel et al., 1998; Teas-
dale et al., 1998; Wilson et al., 1998, 2002, 2007), rang-
ing from 17% (Marmarou, 2001) to 40% (Wilson et al.,
2007) in practices. Previous work has shown that this
could attenuate the true treatment effect and reduces the
power of detecting the efficacy of treatment (Choi et al.,
2002). However, little is known on how different mis-
classification directions or patterns might affect analysis
of treatment effects in double-blinded TBI trials. It would
seem reasonable to suspect that misclassification in a
clinical trial would possibly effect both the treatment and
control groups equally. However, even in this case, there
is a profound effect on the analysis of the treatment ef-
fects (Choi et al., 2002). In clinical practice, nondiffer-
ential misclassification may affect the GOS outcome
through three potential patterns. The random pattern
refers to the misclassification between the adjacent cate-
gories that have an equal rate or chance of being classi-
fied for both treatment groups. The upward pattern means
more true outcome categories are classified into better
outcome categories for both groups. The downward pat-
tern means more true outcome categories are classified
into less optimistic outcome categories for both groups.
The objective of this study is to investigate whether these
three potential patterns of measurement error may have
differential effects on the power of finding treatment dif-
ferences in double blinded TBI trials.
METHODS
Misclassification
Misclassification in this paper is defined as an incor-
rect classification of the GOS outcome in TBI trials. Fur-
thermore, for the purpose of discussing the outcome
analysis of a double-blinded TBI trial, we assume in this
study that the rates of misclassification are the same for
both treatment and control groups. Thus, the outcome
misclassification discussed in this study is nondifferen-
tial or random, and as defined above includes three po-
tential patterns: (1) random, (2) upward, and (3) down-
ward for both treated and control groups. Realizing that
misclassification may be a combination of upward and
downward grading in either the placebo or treatment
group, we selected patterns, which combined both direc-
tions of misclassifications. More specifically, we defined
the “upward” pattern as 20% of patients in both control
and treated groups misclassified to a higher outcome cat-
egory and 10% of patients misclassified in a lower out-
come category. The downward pattern was defined as
20% of patients misclassified in a lower outcome cate-
gory, and 10% of patients misclassified to a higher cat-
egory. These hypothetical percentages of misclassifica-
tion are in the range of GOS misclassification found in
other studies (Anderson et al., 1993; Maas et al., 1983;
Marmarou, 2001; Wilson et al., 1998). Our focus in this
report is to study misclassification applied equally to
placebo and treated groups. However, an imbalance or
non-random misclassification among treated and control
groups is not considered in this report. Among all five
categories of GOS outcome [Death (D), Vegetative (V),
Severe Disability (SD), Moderate Disability (MD), and
Good Recovery (GR)], only the category of death can be
excluded from misclassification, whereas the other four
categories are all subject to misclassification, albeit to a
different degree. To study the effect of misclassification,
it is assumed that a certain rate of misclassification ex-
ists in a patient’s outcome in two adjacent categories.
Patient Data
For analysis of the effect of misclassification on the
outcome differences, we used a dataset of 860 patients
with severe brain injury randomly sampled from two TBI
trials with known differences in outcome (Hukkelhoven
et al., 2002).
For a more detailed analysis of the effect of misclas-
sification on outcome distribution and statistical power,
we used a hypothetical 800-patient dataset (400 patients
in each arm). In this dataset, a 55% favorable outcome
and a 20% mortality outcome distribution was consid-
ered as baseline. For both approaches, the GOS was di-
chotomized into favorable (GR/MD) versus unfavorable
(SD/V/D).
Statistical Analysis
Three patterns of misclassification on dichotomized
GOS were studied: (1) random pattern, where 20% GOS
outcomes were equally misclassified between favorable
and unfavorable outcome categories for both study
groups; (2) upward pattern, where 20% unfavorable out-
comes were misclassified into favorable, and 10% fa-
vorable into unfavorable for both study groups; and (3)
downward pattern, where 20% favorable outcomes were
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misclassified into unfavorable, and 10% unfavorable into
favorable for both study groups. For a dichotomous GOS
outcome (GR/MD vs. SD/V/D), the simulated misclassi-
fication rates were only applied among survivors (i.e., be-
tween GR/MD and SD/V); however, all outcomes, in-
cluding death, were assessed in the final outcome
distribution measurement [i.e., (number of favorable out-
comes/treatment total)–(number of favorable out-
comes/control total).
Power Calculation
In this study, the power was defined as the probabil-
ity of finding the difference between the treatment and
control groups with a 95% two-sided significance. The
calculation was based on a range of hypothetical two-
proportion comparisons. No covariates were considered
to simplify the problem. The powers, under a hypotheti-
cal condition with no misclassification and three simu-
lated cases with misclassification, were compared.
The treatment effect in the hypothetical dataset was
created following a conventional method (Bolland et al.,
1998). For example, 10% treatment effect on a dichoto-
mous GOS outcome [favorable (GR/MD) vs. unfavorable
(SD/V/D)] was defined as an overall 10% outcome shift
from the unfavorable to the favorable outcome in the
treatment group; i.e., the favorable outcome in the treat-
ment group increased by 10%, and the unfavorable out-
come decreased by 10% from the baseline.
Further, recognizing no misclassification on the out-
come of death within the unfavorable outcome category,
we applied the hypothetical treatment effect into the out-
come of death, and the remaining unfavorable outcomes
(i.e., a combined SD and V) individually. For the out-
come of death, 10% treatment effect was defined as a
10% absolute reduction of the baseline numbers, and it
was assumed that 10% of patients’ outcomes were im-
proved from death to better outcome categories includ-
ing V and SD. Finally, the remaining numbers of unfa-
vorable outcomes (SD/V) equaled the total treatment
group minus 10% of the increased baseline favorable out-
come numbers and minus 10% deducted baseline death
numbers. The two-sided Chi-Square test was used for the
dichotomous outcome comparisons.
RESULTS
Effect of Misclassification
The effects of misclassification on the dichotomous
outcome estimation were demonstrated by an actual
phase III TBI trial patient dataset displayed in Table 1.
It was assumed that there were certain rates of outcome
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TABLE 1. EFFECT OF MISCLASSIFICATIONS ON THE OBSERVED DICHOTOMOUS GOS OUTCOMES
GOS after misclassification correctionsb
Observed Random: Upward: Downward:
dichotomous 20% up and 20% up and 10% up and
GOSa 20% down 10% down 20% down
Unfav. Fav. Unfav. Fav. Unfav. Fav. Unfav. Fav.
Groups N D V/SD MD/G D V/SD MD/G D V/SD MD/G D V/SD MD/G
Treatment 430 93 85 252 93 29 308 93 73 264 93 25 312
Control 430 131 81 218 131 35 264 131 73 226 131 30 269
Difference (%)c 7.9 10.2 8.8 10.0
P-valued 0.020 0.002 0.009 0.002
aObserved Glasgow Outcome Scale: D, death; V, vegetative; SD, severe disabled; MD, moderate disabled; G, good recovery.
bThe corrected GOS misclassifications are given by the equation: Fav(Observed)  Fav(True)  Rat1*Fav(True) 
Rate2*[N  D  Fav(True)]. Where 1) Fav(Observed) is the count of the observed favorable outcomes, 2) Fav(True) is the count
of the corrected favorable outcomes, 3) Rate 1 and Rate 2 are the rates of upward and downward misclassification respectively, and
4) N and D represent the group total and the number of deaths respectively. For example, after correcting for 20% upward and 20%
downward misclassification, the equation 252  X  0.2*X  0.2*(430  93  X)_ gives the corrected MD/G  308, and V/SD
 430  93  308  29 for the treatment group; while equation 218  X  0.2*X  0.2*(430  131  X) gives corrected
MD/G  264 ad V/SD  430  131  264  35 for the control group.
cDifference (%) in the favorable outcomes between the treatment and control groups.
dChi-Square Test (two-sided).
categories being misclassified. Thus, reversing the hy-
pothetical misclassified outcome numbers to the observed
outcome data would be helpful in gauging the effect of
misclassification on the outcome analysis, and the three
possible misclassification models were applied.
Random Pattern
In the random pattern, the adjacent outcome categories
have an equal rate of being misclassified for both treat-
ment and control groups. For example, in Table 1, it was
assumed that equal rates (20%) of patients had been mis-
classified as favorable or unfavorable outcome for both
groups. If these misclassified outcome numbers were cor-
rected based on our assumptions, the true underlying
number of patients with the favorable outcomes would
be 308 for the treatment group, 264 for the control, and
the percentage difference in favorable outcomes between
the two groups would be (308 – 264)/430 or 10.2% (p-
value  0.002). The method for calculation is shown in
the Table 1 legend. Before the 20% misclassification cor-
rection, the observed difference is 7.9 and p-value is 0.02.
Thus, misclassification introduces an error of 2.3%
(10.2–7.9).
Upward Pattern
The upward model resulted in an upward trend of mis-
classification for both treatment and control groups,
where the rate of patients being misclassified was higher
(20%) from the unfavorable outcomes to the favorable
outcomes than the rate exchange from the other direction
(10%). If the misclassified outcome numbers were cor-
rected, the number of patients with the favorable out-
comes would be 264 for the treatment group, and 226 for
the control. The actual percentage difference in favorable
outcomes between the two groups would be 8.8 (p-
value  0.009) instead of the observed difference of 7.9
(p-value  0.02). In this case, misclassification intro-
duces an error of 0.9% (8.8–7.9).
Downward Pattern
In the downward model, the rate of being misclassi-
fied was lower (10%) from the unfavorable outcomes to
the favorable outcomes than the rate exchange from the
other direction (20%) for both treatment and control
groups. After the misclassified outcome numbers were
corrected, the number of patients with the favorable out-
come would be 312 for the treatment group, and 269 for
the control. The percentage difference in favorable out-
comes between the two groups would be 10.0 (p-value 
0.002) resulting in misclassification error of 2.1%
(10.0–7.9).
Thus, corrections for all three patterns of misclassifi-
cation demonstrated a potential for greater outcome dif-
ferences and smaller p-values than the observed dataset
if the study assumption was true and the misclassifica-
tion existed in the observed outcome measurement.
Misclassification and Outcome Distribution
Table 2 illustrates the relationship between misclassi-
fication and the dichotomous outcome distribution under
three misclassification models. A hypothetical 800-pa-
tient dataset (400 patients each group) with a 55% fa-
vorable outcome rate and 20% mortality rate was used
for this illustration.
In general, without an outcome difference (i.e., 0%
treatment effect), the misclassified outcome numbers
were the same for both treatment and control groups and
the misclassification only resulted in outcome distribu-
tion shifts, but not in outcome differences for all three
models. However, with an outcome difference (i.e., 5%,
10%, 15% treatment effect), the outcome distributions for
the treatment group were different from the distributions
for the control group. As a result, the misclassified out-
come numbers for the treatment and control groups were
also different. For example, a 20% outcome number ex-
change between the favorable and unfavorable outcome
categories in the random misclassification case caused
the 5%, 10%, and 15% outcome differences to decrease
to 3.2%, 6.4%, and 9.6%. The reduction is 1.8%, 3.6%,
and 5.4%, respectively, from the previous outcome dif-
ferences.
Similarly, in the upward (20% up and 10% down) and
downward (20% down and 10% up) misclassification ex-
amples, after applying the rate exchange between the di-
chotomous outcome categories, the outcome differences
(i.e., 5%, 10%, 15%) decreased to 3.7%, 7.4%, and 11.1%
(Upward), as well as 3.6%, 7.2%, and 10.8% (Down-
ward), which were 1.3%, 2.6%, and 3.9% (Upward), as
well as 1.4%, 2.8%, and 4.2% (Downward) reductions
from the original outcome differences, respectively.
Thus, it is conceivable that the impact from a mis-
classification on a dichotomous outcome measurement is
not only related to the misclassification but also depends
on the outcome distributions of the two study groups. Re-
gardless of the random, upward and downward patterns
of misclassifications, for a fixed rate of misclassification,
the dichotomous outcome difference depends on the size
of treatment effect or the difference in outcome distrib-
ution between the treatment and control groups. This is
illustrated in Table 2, where all three misclassification
examples have revealed that the more the treatment group
differs from the control, the greater the impact of mis-
classification.
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FIG. 1. (A) Effect of random misclassification pattern on the power. The solid line presents the correlation between the power
and the expected treatment effect, and dashed lines present the correlation between the random misclassified treatment effect and
power according to the symbol key. For example, for the case of a 10% treatment effect, a 20% up and down random misclas-
sification would result in a reduction of power from 82% (point a) to 49% (point b) thereby rendering the trial non-significant.
(B) Effect of upward misclassification pattern on the power. The solid line represents the correlation between the power and the
expected treatment effect, and dashed lines represent the correlation between the upward misclassified treatment effect and power
according to the symbol key. For example, for the case of a 10% treatment effect, a 20% up and 10% down (lowest dashed line)
misclassification results in a reduction of power from 82% (point a) to 60% (point b). (C) Effect of downward misclassification
pattern on the power. The solid line represents the correlation between the power and the expected treatment effect, and dashed
lines represent the correlation between the downward misclassified treatment effect and power according to the symbol key. For
example, for the case of a 10% treatment effect, a 10% up and 20% down (lowest dashed line) misclassification results in a re-
duction of power from 82% (point a) to 55% (point b).
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Misclassification and Power
The powers of detecting the expected treatment effect
and the misclassified treatment effect were compared and
are illustrated in Figure 1 using the same hypothetical
800-patient dataset.
An example of the effect of random pattern on the
power is shown in Figure 1a. Under a given treatment ef-
fect (i.e., the improved proportion of the favorable out-
come in the treatment group), the power was inversely
associated with the rate of the misclassification. For ex-
ample, the power of detecting a 10% true treatment ef-
fect with a two-sided 95% significance is 82% (solid
line); however, after the 5%, 10%, and 20% misclassifi-
cations were applied to the expected treatment effect, the
power of detecting the same 10% treatment difference
decreased to 75%, 67%, and 49%, respectively. Clearly,
this was due to the altered outcome difference by the mis-
classification. The higher the misclassification rate, the
smaller the treatment effect and the lower the power.
Figure 1b,c demonstrates the effect of the upward and
downward misclassification patterns on the power. Sim-
ilar results on reducing the power were observed, albeit
in different degrees. If using a power to detect a 10%
treatment effect with a two-sided 95% significance as an
example, the upward pattern with a combination of 5%
up and 2.5% down, 10% up and 5% down, and 20% up
and 10% down were considered to be the rate exchange
between the dichotomous outcome categories, then the
desired 82% power would be decreased to 78%, 72%,
and 60% accordingly. On the other hand, if the situation
was reversed, namely downward pattern with 2.5% up
and 5% down, 5% up and 10% down, and 10% up and
20% down were used as the rate exchanges between the
outcome categories, then the expected 82% power would
be reduced to 76%, 70%, and 55%, respectively.
DISCUSSION
Outcome Measurements and Outcome
Misclassification in Trials of Head Injury
The GOS is widely used for TBI outcome measurement
(Jennett and Bond, 1975) and recommended as primary
endpoint for assessing efficacy of novel therapeutic ap-
proaches in clinical trials. For purposes of analysis in 
clinical trials, the GOS is commonly dichotomized into fa-
vorable versus unfavorable outcome, collapsing the five-
point categorical outcome scale into a binary outcome
measure (Bullock et al., 2002; Choi et al., 1998; Maas et
al., 1997; Narayan et al., 2002; Teasdale et al., 1998; Wil-
son et al., 2002). Despite the acceptance of the GOS as a
global functional outcome measure, it has been criticized
as being insensitive, especially in the more favorable end
of outcome (Bullock et al., 2002; Levin et al., 2001; Teas-
dale et al., 1998). The eight-point extended GOS (GOSE)
has been introduced to increase sensitivity of outcome as-
sessment, and the use of a structured interview is advo-
cated to obtain more consistency in outcome assignment
(Fayol et al., 2004; Wilson et al., 1998). Although the
GOSE offers increased sensitivity, this benefit may be off-
set by a higher rate of misclassification. Recent evidence
indicates an agreement rate as low as 60% in GOSE by
untrained investigators (Wilson et al., 2007).
Misclassification, especially the nondifferential mis-
classification, is a relevant issue in clinical trial design.
Previous work indicated that random misclassification
could mask the true efficacy and reduce the power of
finding a treatment effect (Choi et al., 2002). By under-
standing the consequence of outcome misclassification,
efforts could be made to improve the accuracy and con-
sistency of outcome measurements.
The present study has confirmed the substantial effects
of nondifferential misclassification on outcome analysis
and statistical power under various scenarios. One may
question whether the effects of misclassification are sub-
stantial enough to be important. Clearly, from our analy-
sis, we have found that a treatment effect may be reduced
from 10% to 6.8% by a 20% random misclassification
(i.e., 20% up and 20% down), which is more than suffi-
cient to render a trial ineffective. The effect of misclas-
sification on treatment effect is summarized in Table 3.
Moreover, the scenarios and the rates of misclassifi-
cation investigated are not unrealistic to clinical practice.
Marmarou (2001) conducted a study within the Ameri-
can Brain Injury Consortium to ascertain the reliability
of the GOS rating and found an upward shift of 17.4%
of severe patients to the moderate disability category. An
upward shift of outcome assignment had been previously
reported (Anderson et al., 1993) and is a likely result of
the optimism of the patient’s primary care providers who
compare the improved outcome to the serious condition
immediately after injury, rather than to the healthy pre-
injury status. Conversely, a rigid application of the cri-
teria from the structured interview or questionnaires by
research workers tends to allocate patients to lower out-
come categories (Teasdale et al., 1998; Wilson et al.,
2007). Therefore, nondifferential misclassification may
be found in either the upward or downward direction,
based on different clinical scenarios. It is for this reason
that three patterns were studied in this report.
An Assessment of Three Possible
Misclassification Patterns
To demonstrate the effect of nondifferential misclas-
sification on the outcome, we applied three possible pat-
terns of misclassification on a real Phase III head injury
trial data using five-category GOS outcome distribution
in Table 1. According to the results from previous stud-
ies, we assume that there were certain rates of nondif-
ferential misclassification embedded in the observed
dataset, we corrected the hypothetical misclassified out-
come numbers to the observed data using three models.
After the numbers were corrected, a larger outcome dif-
ference and a smaller p-value were revealed in all three
misclassification patterns.
Therefore, if the misclassification indeed existed in the
past trial dataset as described in this study and as sug-
gested by other studies, then the true outcome difference
would have been larger. More importantly, our study in-
dicated that regardless of which direction the dichoto-
mous outcome was misclassified (i.e., random, upward,
and downward), the effect of nondifferential misclassifi-
cation always tends to reduce the true dichotomous out-
come difference.
It should be noted that the random and the downward
patterns in our examples seemed to have a larger effect
on reducing the outcome difference than the upward pat-
tern. This is likely due to the outcome distribution being
misclassified and the rates of misclassification being ap-
plied. For example, more outcome numbers were ex-
changed from the category of MD/GR (i.e., 20%
MD/GR  (0.2)*(252)  50) with the numbers of V/SD
in the random or downward cases, as compared with the
numbers that were exchanged (10% MD/GR 
(0.1)*(252)  25) in the upward case. Thus, it is reason-
able to understand why the random and the downward
patterns had a larger impact on the outcome difference
in our example.
In summary, the true outcome difference is always af-
fected more by a higher misclassification rate and a larger
difference in outcome distributions between the treatment
and control groups. Therefore, any procedures that min-
imize the misclassification, such as proper outcome mea-
surement techniques and the methods for improving the
inter-observer agreement, should be indicated according
to this study. Experience in the recent Phase III clinical
trial on Dexanabinol showed that training of outcome as-
sessors can be highly effective (Wilson et al., 2007).
Differential Effects of Misclassification 
in Treatment and Control Groups
Although it is generally assumed that the rate of the
misclassification under a blinded clinical trial condition
is the same for both control and treatment groups (i.e.,
nondifferential or random misclassification), the effect of
the misclassification on these two are unlikely to be the
same in the presence of a treatment effect. This is a con-
sequence of the different outcome distribution between
the treatment groups, as illustrated in Table 2.
For example, in the random misclassification (20%
up/down) case, with no treatment effect, the misclassi-
fied outcome numbers are the same for both treatment
and control groups; the misclassification only resulted in
an outcome distribution shift but not in an outcome dif-
ference. However, with a treatment effect (i.e., 5%, 10%,
15%), the misclassified outcome numbers for the treat-
ment and control groups are no longer the same, i.e., more
patients’ outcome in the treatment group are affected by
the misclassification due to a larger outcome difference.
Thus, instead of having an 5%, 10%, 15% in treatment
effect, only a 3.4%, 6.8%, 10.2% outcome difference re-
sults, which represents a 1.6%, 3.2%, and 4.8% reduc-
tion of the previous outcome difference, respectively.
The other two patterns followed a similar trend as well.
Figure 2 shows the example of correlation between up-
ward misclassifications and reduction of treatment effect
using same hypothetical 800-patient data as in Table 2. For
a fixed rate of misclassification, the outcome difference
depends on the size of treatment effect or the difference in
outcome distribution between the treatment and control
groups. For example, after a 20% upward misclassifica-
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TABLE 3. REDUCTION OF TREATMENT EFFECT AND POWER BY MISCLASSIFICATION
Patterns of misclassificationa Treatment effect reduction Power reductionb
Random
10% up/down 10% → 8.4% 80% → 66.5%
20% up/down 10% → 6.8% 80% → 48.6%
Upward
10% up 10% → 9.2% 80% → 76.6%
20% up 10% → 8.4% 80% → 69.9%
aMisclassification on both treatment and control arms, assume 55% favorable outcome and
20% mortality.
bTwo-arm trial, n  800; expected treatment effect  10%; power  80% and 95% two-
sided significance.
tion, the expected 5%, 10%, 15%, and 20% outcome dif-
ferences were reduced to 4.2%, 8.4%, 12.2%, and 16.6%,
respectively. On the other hand, for a fixed treatment ef-
fect, the effect of misclassification on outcome difference
depends on the rate of misclassification. For example, af-
ter 5%, 10%, 20%, and 30% biased upward misclassifica-
tion, an expected 10% treatment effect was reduced to
9.4%, 9.2%, 8.4%, and 7.6%, respectively.
The implication here is that, if a study drug does have
an effect on improving the patients’ outcome, the treat-
ment group is likely to be affected more by the misclas-
sification than the control group. The more a treatment
differs from the control, the greater the number of pa-
tients affected by the misclassification, leading to a
greater reduction in the true outcome difference.
It is important to note that the demonstration on the
dichotomous outcome distribution can also be applied to
more than two category distributions. For example, if
there is a larger difference between MD and GR, the true
difference between these two categories will be affected
more by misclassification. Likewise, if a larger differ-
ence exists between SD and MD, the actual difference
between these two will be decreased more as a result of
the misclassification. This topic will be studied in greater
detail in the future.
Dealing with Misclassification
Since all GOS categories can be misclassified except
death and as the affected outcome numbers are associ-
ated with the treatment effect and/or the outcome distri-
bution, one might relate the issue to the choice of out-
come measurements in head injury clinical trials. One
study has suggested that an increase in outcome cate-
gories leads to an increase in misclassifications, and sev-
eral other studies have proved that inter-observer dis-
agreement is much higher in the eight-category GOS than
that in the five-category GOS (Choi et al., 2002; Maas et
al., 1983). These observations underline the notion that
the outcome measurement with fewer outcome categories
might be less affected by the misclassification. A careful
balance will need to be sought between the desire for
more sensitive expanded outcome measures and adverse
effects of misclassification.
We suggest that both outcome misclassification and
the sensible outcome measurement are important issues
in the TBI trial design, which, in turn, is directly associ-
ated with the success of a trial. However, both the strat-
egy to minimize the outcome misclassification, and to se-
lect a sensible outcome measurement should be
considered separately. Although outcome misclassifica-
tion is unavoidable, it is possible that errors in classifi-
cation may be reduced. Accordingly, procedures such as
structured interviews, proper outcome information re-
sources, quality assurance of outcome evaluation and
properly trained personnel have been previously shown
to be successful approaches of minimizing the misclas-
sification (Marmarou, 2001; Pettigrew et al., 2003; Wil-
son et al., 1998, 2007). These measures as well as de-
veloping new strategies are recommended in the clinical
trial design.
On the other hand, carefully examining the outcome
distribution from Phase II trials and selecting a sensitive
outcome measurement to match each individual outcome
distribution should be considered. For instance, if a treat-
ment effect was mainly focused between the moderate
and severe disability categories or other adjacent GOS
categories, a dichotomous outcome would be a better
choice over more GOS categories (Choi et al., 2002).
However, if more or all categories of the GOS are af-
fected by the treatment, then the dichotomous GOS would
be less powerful than using more GOS categories
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FIG. 2. Reduction of treatment effect by upward outcome misclassification. The solid line represents the expected treatment ef-
fect, and dashed lines represent the reduction of treatment effect by the upward misclassifications according to the symbol key.
For example, for the case of a 10% treatment effect, a 30% up (lowest dashed line) misclassification results in a reduction of
treatment effect to 7.6%, which is a 2.4% reduction from the expected 10% treatment effect.
Effect of Misclassification on Power 
and Sample Size
Recognizing that outcome misclassification has a sig-
nificant potential to reduce the true treatment effect, one
would naturally relate this consequence to the power and
sample size of a trial design. For a typical Phase III TBI
trial, a sample size of 800 patients (i.e., 400 patients in
treatment group, 400 in placebo group) is required in or-
der to detect an absolute treatment effect that increases
the proportion of favorable outcomes from 50% to 60%,
with 80% power and 5% significance. We used a simi-
lar design to examine the effect of outcome misclassifi-
cation on the desired power in the TBI trial. The corre-
lation between the power and three potential patterns of
misclassification was depicted in Figure 1.
As one might expect, in parallel with the effect of re-
ducing the true outcome difference, all three patterns of
misclassification have an inverse effect on the power. For
instance (Fig. 1a), without misclassification, the expected
power of detecting a 10% treatment effect (i.e., improv-
ing favorable outcome from 55% to 65% in the treatment
group in our example) was 82%; with the same condi-
tion and a 10% random (i.e., 10% up and 10% down)
misclassification for both study groups, the power of de-
tecting such effect decreased to 67%; similarly, the pow-
ers under the upward (i.e., 10% up and 5% down), and
the downward (i.e., 10% down and 5% up) misclassifi-
cation condition reduced the power from 82% to 72%
and 70%, respectively. Clearly, the examples shown in
this study demonstrate that the desired power to detect
the treatment effect could be compromised by misclassi-
fication of the dichotomous GOS outcome; the greater
the number of outcomes misclassified, the greater the de-
gree of power compromised.
Compensation for Reduced Power Due 
to Misclassification
As misclassification reduces power, it would seem rea-
sonable to simply increase the sample size to compen-
sate for the power reduction. This can be done. However,
increasing the sample size can only raise the power but
cannot compensate for treatment effect due to misclassi-
fication. Using our previous example in Table 3, a 10%
random misclassification can reduce the original 10%
treatment effect to 8.4%, and the power was subsequently
reduced from 80% to 66.5% for detecting 8.4% treatment
effect. In this example, one can increase the sample size
from 800 to 1094 in order to raise the power from 66.5%
to 80% for detecting 8.4% treatment effect, but still, the
increased sample size cannot compensate the 1.6%
(10%–8.4%) treatment reduction. This further empha-
sizes the importance of designing procedures to minimize
the effect of misclassification. In summary, the only way
to blunt the reduction of treatment effect is to reduce mis-
classification.
CONCLUSION
All three patterns of nondifferential misclassification
act to attenuate the treatment effect and reduce the power
of detecting the true treatment effect. In the case of a pos-
itive drug effect, misclassification leads to a conservative
estimation of the true efficacy. The magnitude of such
influence not only depends on the size of the misclassi-
fication, but also on the magnitude of treatment effect.
Nondifferential misclassification directly reduces the
power of finding the true treatment effect. If the outcome
of the treatment arm is worse, then misclassification acts
to blunt the difference between placebo and treatment.
Thus, an awareness of this procedural error and methods
to reduce misclassification should be incorporated in TBI
clinical trials.
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